Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector
Source: SeekingAlpha
2025-05-08 18:22:50 ET
Summary
- I've had a mixed experience with Fate Therapeutics, initially noting rallies but later observing a significant 75% decline, questioning market enthusiasm.
- Revisiting FATE after a year, I aim to determine if the market's lack of interest is justified or a broader cell therapy sector issue.
- The article explores FATE's pipeline updates, financial overview, and strengths and risks to provide a comprehensive investment thesis.
- Bottom-line: Assess whether FATE's current market position reflects its true potential or is merely a victim of sector-wide disinterest.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector
Fate Therapeutics Inc.
NASDAQ: FATE
FATE Trading
-5.02% G/L:
$1.135 Last:
521,183 Volume:
$1.18 Open:
FATE Latest News
March 04, 2026 04:05:00 pm
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2026 04:05:00 pm
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
March 03, 2026 10:02:00 am
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
February 26, 2026 09:00:00 am
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
FATE Stock Data
$128,041,041
108,996,378
1.54%
45
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
